PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Nomogram Predicts Suboptimal CRRT Downtime in Critically Ill Patients

continuous renal replacement therapyCRRTacute kidney injuryprediction modelnomogramplasma exchangeanticoagulationregional citratecritical caredowntimeretrospective cohort Clinical Pharmacy Practice

Background Information

CRRT downtime risks can now be predicted and mitigated in the ICU.

Downtime during continuous renal replacement therapy (CRRT) can worsen patient outcomes, increasing the risk of mortality. The study identified five risk factors for downtime: filter replacements, agitation, plasma exchange, catheter dysfunction, and out-of-unit transport, with a nomogram showing good predictive accuracy (AUCs 0.789 to 0.835). ICU nurses can use this predictive model to pinpoint high-risk CRRT days, improving patient management and reducing adverse events related to excessive downtime. Identifying and managing risks for CRRT downtime can enhance treatment efficacy and patient care in the ICU.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Pang B, Zhang J, Wu Y, Kang Q, Dong K, Guo S, Yin Y

Citation: Pang B, Zhang J, Wu Y, et al. Analysis of Factors Influencing Downtime During Continuous Renal Replacement Therapy in Critically Ill Patients and Construction of a Prediction Model. Nursing in critical care. 2026;31(5):e70664. doi:10.1111/nicc.70664

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →